Skip to main content
OpenTrials
Completed

NCT Number: NCT03335839

Adjunctive, Low-dose tPA in Primary PCI for STEMI

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

University of Calgary - Foothills Medical Centre, Calgary, Alberta, Canada

Loading trial locations.

About this study

STRIVE is a prospective, 3-arm, parallel group, blinded, randomized controlled trial evaluating the efficacy of a novel approach to prevent and treat microvascular obstruction thereby reducing major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with STEMI undergoing primary PCI and,
  • ECG changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in 2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥8mm) and,
  • Randomization within 6 to 12 hours of symptom onset and,
  • Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing.

Exclusion criteria

  • Active internal bleeding or high risk of bleeding or any prior intracranial bleeding.
  • Any other absolute or relative contraindication to fibrinolytic therapy.
  • Administration of a fibrinolytic ≤24hrs prior to randomization.
  • Cardiogenic shock on presentation.
  • Left bundle branch block (excluded because the ECG cannot be evaluated for ST segment resolution, an outcome of the study).
  • Planned upfront use of a glycoprotein IIb/IIIa inhibitor.
  • Any medical, geographic, or social factor making study participation impractical or precluding 1 month follow-up.

Treatment and study plan

tissue plasminogen activator

Drug

Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.

Saline

Other

Placebo

Primary outcomes

  1. MACE OR Myocardial Blush Grade 0/1 OR Distal Embolization OR Failure to Achieve ≥50% ST-segment Resolution

    Time frame: 30 days post-randomization

    The primary efficacy variable is the binary composite outcome with the following components:

    • The occurrence of any of the MACE outcomes (cardiovascular death, myocardial re-infarction, cardiogenic shock and new onset heart failure) at 30 days post-randomization.
    • Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)).
    • Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI).
    • Failure to achieve ≥50% ST-segment resolution post-procedure.

Secondary outcomes

  1. The Composite of MBG grade 0/1 or Distal Embolization or Failure to Achieve ≥50% ST-segment Resolution

    Time frame: 30 minutes post-PCI

    • Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)).
    • Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI).
    • Failure to achieve ≥50% ST-segment resolution post-procedure of the summed absolute ST-segment deviations across associated and reciprocal leads at 30 minutes post-PCI
  2. The Composite of MBG grade 0/1 or Distal Embolization

    Time frame: Immediately following PCI

    • Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)).
    • Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI).
  3. MBG Grade 0/1

    Time frame: Immediately following PCI

    Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)).

  4. Distal Embolization

    Time frame: Immediately following PCI

    Post-procedural distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI.

  5. Failure to Achieve ≥50% ST-segment Resolution.

    Time frame: 30 minutes post-PCI

    Failure to achieve ≥50% ST-segment resolution of the summed absolute ST-segment deviations across associated and reciprocal leads at 30 minutes post-PCI.

  6. Time to the First Occurrence of MACE

    Time frame: 30 days post-randomization

    Time to the first occurrence of MACE (composite of cardiovascular death, myocardial re-infarction, cardiogenic shock or new onset heart failure) over the duration of 30 days follow-up.

Other outcomes

  1. Time to the First Occurrence of Major Bleeding Over the Duration of 30 Days Follow-up

    Time frame: 30 days post-randomization

    Clinically overt, bleeding with at least one of the following criteria:

    • Fatal or
    • Symptomatic intracranial hemorrhage or
    • Retroperitoneal hemorrhage or
    • Intraocular hemorrhage leading to significant vision loss or
    • Decrease in hemoglobin of ≥ 3.0 g/dL (with each blood transfusion unit counting for 1.0 g/dL of hemoglobin or requiring transfusion of two or more units of red blood cells or equivalent of whole blood) or
    • Requiring surgical intervention to stop the bleeding
  2. Time to the First Occurrence of Major or Clinically Significant Bleeding Over the Duration of 30 Days Follow-up

    Time frame: 30 days post-randomization

    Clinically overt, bleeding with at least one of the following criteria:

    • Fatal or
    • Symptomatic intracranial hemorrhage or
    • Retroperitoneal hemorrhage or
    • Intraocular hemorrhage leading to significant vision loss or
    • Decrease in hemoglobin of ≥ 3.0 g/dL (with each blood transfusion unit counting for 1.0 g/dL of hemoglobin or requiring transfusion of two or more units of red blood cells or equivalent of whole blood) or
    • Requiring surgical intervention to stop the bleeding Any other clinically significant bleeding not meeting the definition for major bleeding and resulting in hospital admission, prolonged hospital stay or transfusion of one unit of blood (whole blood or packed red blood cells (PRBC))
  3. Failure to achieve ≥ 50% resolution

    Time frame: 30 minutes post-PCI

    Failure to achieve ≥ 50% resolution of the ST-segment value (worst lead) at 30 minutes post-PCI

  4. All-Cause Mortality at 30 Days

    Time frame: 30 days post-randomization

    The composite of cardiovascular or non-cardiovascular death

  5. Flow Velocity as Measured by the Corrected TIMI Frame Count (Continuous)

    Time frame: Immediately following PCI

    Continuous measure of TIMI frame count as reported by Angiographic Core Lab.

  6. Post-Procedural TIMI Flow Grade 3

    Time frame: Immediately following PCI

    Full perfusion of the infarct vessel with normal flow.

  7. Time to the First Occurrence of Composite of Cardiovascular Death (CV), Cardiogenic Shock and New Onset Heart Failure (HF) Over the Duration of 30 Days Follow-up

    Time frame: 30 days post-randomization

    All deaths with a CV or unknown cause will be classified as CV. Only deaths due to a documented non-CV cause will be classified as non-CV.

    At least one of the following:

    • SBP <90mmHg and not responsive to fluid resuscitation and/or HR correction for at least 1 hr
    • Need for vasopressor/inotropic therapy to maintain SBP >90mmHg for at least 1 hr, believed to be secondary to cardiac dysfunction and associated with Pulmonary edema/Hypoperfusion/Cardiac Index <2.0L/min New onset HF as per NYHA and defined as decision to treat with IV diuretic, inotropic agent or vasodilator with at least one of the following: presence of pulmonary edema or pulmonary vascular congestion on chest radiograph thought to be due to HF / râles reaching above the lower 1/3 of the lung fields thought to be due to HF / pulmonary capillary wedge pressure or left ventricular end-diastolic pressure = 18mmHg. In the case of new onset outpatient HF, re-admission to an acute care facility is required.

Sponsors and collaborators

Lead sponsor

Population Health Research Institute

Other

Collaborators

  • Heart and Stroke Foundation of Canada

Registry information

Official study title

Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction

Acronym: STRIVE

Important dates

Study start
2018
Primary completion
2024
Study completion
2025
First posted
Nov 8, 2017
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.